Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C

Table 1 Characteristics in patients of refractry chronic hepatitis C

	Control	IFN	ACE-I	IFN+ACE-I
No. of patients	10	7	7	11
Mean age ± SD (yr)	60 ± 7	60 ± 9	58 ± 9	62 ± 8
Sex (M/F)	6/4	3/4	4/3	5/6
Serum HCV-RNA1 (M copies/L)	632 ± 120	641 ± 131	620 ± 106	628 ± 108
Genotype (1 b/others)	9/1	6/1	7/0	10/1

¹Data represent mean ± SD.

Table 2 Changes of seveal markrs in patients of refractry chronic hepatitis C (mean ± SD)

	Control		IFN		ACE-I		IFN+ACE-I
	Before	After	Before	After	Before	After	Before	After
Mean BP (mmHg)	132 ± 14	130 ± 12	130 ± 14	128 ± 13	141 ± 16	128 ± 12a	142 ± 15	130 ± 12a
HCV-RNA (M copies/L)	632 ± 120	604 ± 117	641 ± 131	598 ± 95	620 ± 106	613 ± 110	628 ± 108	586 ± 90
S-Cre (mg/L)	9 ± 2	9 ± 2	9 ± 2	9 ± 1	9 ± 1	8 ± 1	8 ± 1	8 ± 1

^aP < 0.05 vs before treatment.